Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.7.7.7 (DNA polymerase)
17,007 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Proliferating cells, independent of their position in the cell cycle, contain a primer-dependent alpha-DNA polymerase (PDP); we have, therefore, tested the feasibility of the PDP assay in breast, ovarian, and head and neck tumors. Experimental results demonstrate that the PDP labeling index (PDP-LI) is constantly superior to the thymidine labeling index (TLI), which indicates the percentage of S phase cells. The PDP-LI/TLI ratios observed were 5.0 in breast cancer, 3.6 in ovarian cancer, and 2.5 in head and neck tumors. Higher PDP-LI scores have been obtained in metastatic breast tumor samples (PDP-LI = 8.8) compared to nonmetastatic tumors (PDP-LI = 4.9).
...
PMID:Proliferative activity of human solid tumors evaluated by thymidine labeling index and primer-dependent alpha-DNA polymerase. 380 72

We have evaluated the feasibility of a cytokinetically oriented regimen based on the induction of cell recruitment by diethylstilbestrol (DES) in locally advanced human breast cancer. Tumor proliferative activity was evaluated by the thymidine labeling index and the primer-dependent alpha-DNA polymerase labeling index, which gives an in vitro estimation of the growth fraction. Sixteen previously untreated patients received DES (1 mg daily for 3 days) followed by FAC [5-fluorouracil (600 mg/m2): Adriamycin (50 mg/m2): Cytoxan (600 mg/m2)] i.v. on day 4 every 21 days. Radical surgery was delayed to allow for three DES-FAC regimens in responsive patients. Proliferative activity on tumor biopsies was evaluated immediately before and after treatment with DES, 24 h after chemotherapy and, in nine patients, at the time of radical surgery. DES was able to induce a significant increase in thymidine labeling index in 8 of 16 patients, while the primer-dependent alpha-DNA polymerase labeling index was significantly increased in 13 of 16 tumors, independently of their estrogen receptor content. Subsequently administered chemotherapy induced an early decrease in tumor proliferation. In the nine patients submitted to surgery after three DES plus FAC courses, the average thymidine labeling index and primer-dependent alpha-DNA polymerase labeling index were 27.8 and 73% of the pretreatment values. Our preliminary results provide the rationale for the design of new therapeutic schemes in which antitumor drugs are given at the time of estrogen-induced tumor cell recruitment. Further extended studies are required to establish whether induction of tumor cell recruitment will actually translate into appreciable improvement of the clinical response to chemotherapy.
...
PMID:Chemotherapy following estrogen-induced expansion of the growth fraction of human breast cancer. 405 64

The feasibility of a cytokinetic chemotherapy based on estrogenic recruitment has been evaluated in 5 patients, affected by locally advanced breast cancer with low or absent receptor content. Tumor proliferative activity was evaluated by the thymidine labeling index (TLI) and the primer-dependent alpha DNA polymerase assay (PDP-LI) which gives an in vitro estimation of tumor growth fraction. The patients have been treated with diethylstilbestrol (DES) 1 mg/die. for 3 days, followed by FAC (5-Fluorouracil 600 mg/m2, Adriamycin 50 mg/m2, Cytoxan 600 mg/m2) i.v. on day 4 q. 21 days. Radical surgery was performed after 3 DES-FAC regimens. Tumor biopsies for evaluation of tumor proliferative activity were performed immediately before and after DES and 24 h after chemotherapy. Our results demonstrate that DES was able to induce an increase in TLI in 3/5 of the patients while the PDP-LI was significantly increased in 5/5 of the patients; subsequent chemotherapy induced a sharp decrease in tumor proliferation. These results provide the rationale for the design of cytokinetic regimens where chemotherapy is administered at the time of estrogen induced tumor cell recruitment.
...
PMID:Estrogen induced expansion of the growth fraction in receptor negative human breast cancer. 409 31

We have recently established four new human breast cancer cell lines that were characterized as being of human mammary origin. We examined these cell lines for particles morphologically resembling retroviruses by electron microscopy, for extracellular and intracellular particles containing high-molecular-weight RNA and RNA-directed DNA polymerase by biochemical assays, and for mouse mammary tumor virus (MMTV)-related sequences in the cell genomes by molecular hybridization. An extensive search for budding particles by thin-section electron microscopy of cells did not provide evidence for retrovirus-like particles. Similarly, 1000- to 2000-fold concentrated samples of medium harvested from 10(8) cells did not contain particles of a density of 1.14 to 1.16 g/ml containing RNA-directed DNA polymerase. Compared with DNA polymerase activity of MMTV, and taking into account the particle weight and protein content of retroviruses, we estimate that, if these cells produce retrovirus-like particles, this production would be less than 1.6 particles/cell every 24 to 72 hr. The hybridization of cell DNA with MMTV complementary DNA also did not show detectable amounts of virus-related sequences in the cell genome. Analysis of the hybridization results suggested that, if the human breast cells contained MMTV-related sequences, they must be present in less than one copy per 100 cells. Thus, we have obtained no convincing evidence for the presence of retrovirus-like particles or subviral components in these cells. It is of course possible that these cells contain virus information but at levels below the sensitivity of our assay procedures.
...
PMID:Search for retrovirus-like particles in human breast cancer cells in culture. 616 39

Two DNA polymerases with properties of viral RNA-directed DNA polymerase were found in the placenta of a patient with breast cancer. Both enzyme activities were purified by column-chromatographic procedures or by preparative isoelectric focusing. The most distinguishing feature of the two enzymes is their specificity to transcribe (rA)n . (dT)12 or (rC)n . (dG)18. The two enzymes differ with respect to their elution profiles from the phosphocellulose column, isoelectric point, molecular weight, bivalent-cation requirements and thermal stability. Serological analysis of the (rA)n . (dT)12-activated enzyme showed that this enzyme is immunologically not related to DNA polymerase-gamma, or to any of the reverse transcriptases purified from retroviruses of avian, murine and subprimate origin. However, the activity of this enzyme was neutralized by antibodies to reverse transcriptase purified from human spleen of a patient with myelofibrosis [Chandra & Steel (1977) Biochem. J. 167, 513-524]. Attempts to purify reverse transcriptase of normal human placenta were repeatedly unsuccessful. Once the crude homogenate of normal placenta was freed from endogenous nucleic acids, no (rC)n . (dG)18-dependent activity cold be detected.U
...
PMID:Evidence for two forms of reverse transcriptase in human placenta of a patient with breast cancer. Purification and biochemical characterization of the enzymes. 617 35

The expression of a mouse mammary tumor virus is inducible by hormones, and the virus contains a hormone-responsive element. Viral particles and RNA-directed DNA polymerase (RDDP, EC 2.7.7.7; reverse transcriptase) are both detectable in human breast tumors but the frequency and significance of these findings are unknown. Breast tumor biopsy specimens (from either the primary site or a metastasis), frozen in liquid nitrogen at the time of surgery, were routinely obtained to determine estrogen receptor (ERP) concentration. A sample of the tissue was pulverized, homogenized and centrifuged at low speed to remove nuclei and mitochondria. The supernate was then centrifuged at 225,000 g to obtain the cytosol fraction for estrogen and progestin receptor (PgR) assays. Partially purified membranes for the RDDP assays were prepared from the high-speed pellet by discontinuous sucrose density gradient centrifugation. The RDDP assay involved measuring primer-dependent poly(dT) synthesis in the presence of poly(A) as template and oligo-(dT)12-18 as primer. To date, we have studied biopsy specimens from 46 patients with breast cancer. 27 (59%) had ERP and 23 (50%) were RDDP-positive. There was no significant correlation between ERP concentration and RDDP activity. PgR data were available on 36 of the patients; 17 (47%) were positive. No correlation between RDDP and PgR was apparent. Similarly, there was no correlation between RDDP and clinical stage of the disease.
...
PMID:RNA-directed DNA polymerase activity in human breast cancer biopsy specimens. Relation to estrogen receptor protein. 620 38

Taking advantage of the fact that estrogens can stimulate proliferation of antiestrogen-inhibited MCF-7 cells has enabled us to study molecular events involved in steroid-mediated growth of tumor cells, using a breast cancer cell line which otherwise is affected very little in its growth by estrogens. Under these growth conditions, estradiol stimulates DNA polymerase activity in a manner analogous with reported estrogen effects on enzyme activity in normal target tissues. We also observed dissociation of estrogen effects on cell growth and PgR stimulation, indicating that PgR induction and estrogen-mediated cell division may involve separate control mechanisms. The relative rate of synthesis of the 24,000 molecular weight protein is also increased under these conditions of estrogen-stimulated cell growth. Since increased synthesis of the 24,000 molecular weigh protein was determined not to be a reflection of different stages of cell growth, we suggest that this protein is regulated specifically by estrogens and that it may be a marker of estrogen stimulated growth of human breast tumor cells.
...
PMID:Estrogen regulation of growth and specific protein synthesis in human breast cancer cells in tissue culture. 734 12

We have investigated the effects of estrogens and antiestrogens on cellular DNA-dependent DNA polymerase activity in human breast cancer, using as a model the MCF-7 human breast cancer cell line which contains estrogen receptor. 17 beta-Estradiol had little if any effect on cytosol DNA polymerase activity or growth (total DNA per flask) of MCF-7 cells. Incubation of the cells for 4 to 6 days with the antiestrogen nafoxidine, however, resulted in a dose-dependent reduction in cytosol DNA polymerase activity to one-half that observed in untreated cells. Enzyme activity in antiestrogen-treated cells was restored to levels contained in untreated cells by removing antiestrogen from the growth medium and incubating the cells for an additional 4 days with 17 beta-estradiol. The restoration required estrogenic steroids specifically, and the time course, magnitude, and dose dependence of the response were similar to estrogen-stimulated increases in DNA polymerase activity described in other estrogen target tissues. Estrogen-mediated reversal of antiestrogen suppression of DNA polymerase activity was paralleled by increases in total DNA synthesis.
...
PMID:Effects of estrogen and antiestrogen on DNA polymerase in human breast cancer. 737 Oct 1

The biological effects of 17 alpha-estradiol (17 alpha-E) and its interaction with estrogen receptors were studied in the MCF-7 human breast cancer cell line. Competition for [3H]17 beta-estradiol ([3H]17 beta-E) binding shows that 17 alpha-E binds to receptor with high affinity and has a dissociation constant (Kd) estimated to be 0.7 nM. Upon binding with 17 alpha-E, the cytosol receptor is translocated to the nucleus and is then rapidly depleted or processed in the same manner as the 17 beta-E-receptor complex. The nuclear 17 alpha-E-receptor complex was determined to be biologically active by its ability to stimulate an increase in the progesterone receptor content and to reverse antiestrogen inhibition of cellular proliferation and DNA polymerase activity. The estrogenic potency of 17 alpha-E, estimated from the dose-response curves as the median effective dose in stimulating progesterone receptor content and in reversing antiestrogen inhibition, is about one tenth the potency of 17 beta-E. Competition curves show that 17 alpha-E binds to the cytosol estrogen receptor with about one third the affinity of 17 beta-E, so the correlation between relative binding affinity and biological potency is not perfect. The correlation, however, is reasonably good compared with that in animal studies, in which 17 alpha-E displays negligible biological activity. Gas chromatography and mass spectrometry rule out the possibility that the observed estrogenic activity of 17 alpha-E was due to contamination of the preparation with the more active 17 beta-E. The enhanced estrogenic potency of 17 alpha-E in MCF-7 cells raises the question of whether the stereospecificity and, thus, the sensitivity of the estrogen receptors in breast cancer cells may be different than those in normal target tissues. Enhanced estrogenic activity may also be due simply to the nature of the tissue culture system, which allows continuous exposure of the cells to hormone; a condition which may not be achieved in some animal studies.
...
PMID:17 alpha-Estradiol is a biologically active estrogen in human breast cancer cells in tissue culture. 740 75

Aromatization of androstenedione to estrone in peripheral tissues is the major source of estrogen in postmenopausal women. The aromatase enzyme complex, which mediates the conversion of androstenedione to estrone, is present in several tissues, including adipose tissue and normal and malignant breast tissues. Aromatase activity is detectable in 50-60% of breast tumors, but the contribution that tumor aromatase makes to estrogen concentration in tumors and whether the estrogen formed is biologically important remains a controversial matter. Since concentrations of androstenedione are higher in tumors than in blood, and tumor aromatase activity in vivo may be enhanced by growth factors and by cytokines, the contribution of tumor aromatase to tumor estrogen levels may be higher than suggested by the original calculations. Measurements of tumor aromatase, tumor estrone concentrations, and DNA polymerase alpha activity (a marker of cellular proliferation), in samples obtained before and after treatment with the aromatase inhibitor 4-hydroxyandrostenedione, lend some support to a biological role for estrone formed locally.
Breast Cancer Res Treat 1994
PMID:The role of aromatase in breast tumors. 794 6


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---